These findings suggest that HCQ treatment is associated with a dose-dependent suppression of c-myc gene expression in MDA-MB-231 breast cancer cells, indicating a potential regulatory role for HCQ in modulating c-myc mRNA levels. This evidence concerns the gene MYC and breast carcinoma.